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Abstract Background: Ethanol is included in certain injectable preparations of anti-
cancer drugs to increase their solubility. Since the volume of ethanol in these
preparations is approximately half of the total injection volume, the potential
inhibitory effects of ethanol on the central nervous system cannot be dis-
regarded, especially considering that patients may drive immediately after
administration of the medication. Therefore, the concentration of ethanol
was examined in exhaled breath after administration of paclitaxel, an anti-
cancer medication containing ethanol.
Methods: The ethanol concentration in exhaled breath immediately after an
intravenous infusion of paclitaxel was measured in 30 patients, using a bal-
loon-type gas detector tube. Correlations between the concentration of
ethanol in exhaled breath and the total amount of ethanol administered or the
intravenous infusion speed were calculated.
Results: The mean ethanol concentration in exhaled breath was 0.028 –
0.015mg/L. The correlation between the ethanol concentration in exhaled
breath and the total dose of ethanol was weak (R2= 0.25; p = 0.055), while the
intravenous infusion speed showed a stronger positive correlation with the
concentration of ethanol in the breath (R2= 0.49; p = 0.11). The maximum
concentration of ethanol measured in exhaled breath (0.06mg/L) was equiv-
alent to 40% of the threshold for drunk driving, as specified in the Road
Traffic Act in Japan.
Conclusion: In this study, no patient had a breath ethanol concentration ex-
ceeding the legal threshold for drunk driving. However, it is still advisable for
patients to avoid driving after receiving paclitaxel injections. When driving
cannot be avoided, patients should wait for a sufficient time after receiving
the injection before driving.
SHORT COMMUNICATION Drugs R D 2012; 12 (3): 165-1701179-6901/12/0003-0165
Adisª 2012 Aomori et al., publisher and licensee Springer International Publishing AG. This is an open access article published under
the terms of the Creative Commons License ‘‘Attribution-NonCommercial-NoDerivative 3.0’’
(http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits non-commercial use, distribution,
and reproduction, provided the original work is properly cited and not altered.
Background
Paclitaxel is an antineoplastic drug isolated from
a bark extract of Taxus brevifolia (Taxaceae).[1]
The governments of the US and Canada ap-
proved paclitaxel for sale in 1992, and a paren-
teral solution of paclitaxel subsequently became
commercially available in Japan in 1997. Paclitaxel
induces formation of excess disorderedmicrotubules
by promoting microtubule polymerization and
stability. Since paclitaxel inhibits depolymeriza-
tion of microtubules,[2,3] cell division is inhibited.
Thus, paclitaxel has antitumor activity. Paclitaxel is
used clinically in the treatment of ovarian, breast,
endometrial, stomach, and non-small cell lung
cancers in Japan. Themain adverse drug reactions
to paclitaxel include gastrointestinal symptoms,
peripheral neuropathy, arthralgia, muscular pain,
nausea and vomiting, epilation, and pyrexia.
Paclitaxel tends to be soluble in N,N-dime-
thylacetamide, acetonitrile, methanol, and etha-
nol but is relatively insoluble in water. Because
50% ethanol is used as the solvent for clinical
paclitaxel injections,[4] we hypothesized that im-
pairment of specific central nervous system (CNS)
functions by ethanol or its cleavage product,
acetaldehyde, as well as adverse reactions related
to intoxication, may occur following treatment
with this preparation. Thus, the possibility of
adverse reactions following intake of ethanol
accompanying paclitaxel administration should
not be overlooked.
Since many hospitals in Japan are located in
rural areas and are not conveniently accessible by
public transportation, most patients drive to the
hospital. Thus, it is important to consider the
possible CNS depressant actions of ethanol con-
tained in injectable drug formulations, in order to
reduce the risk of serious car accidents. Further-
more, in theRoad Traffic Act in Japan, the breath
ethanol concentration that constitutes drunk driving
is 0.15mg/L.[5] This threshold is lower than those in
theUK,USA, andCanada (0.40mg/L), and those
in Australia, Germany, and France (0.25mg/L).
It is important to ensure that patients who receive
paclitaxel injections containing ethanol do not
have breath ethanol concentrations exceeding the
legal threshold. Although research on plasma
ethanol concentrations following paclitaxel ad-
ministration has been published previously,[6]
only a few reports have evaluated the correlation
between ethanol intake during chemotherapy and
the ethanol concentration in exhaled breath.
Here, we investigated the concentration of
ethanol in exhaled breath after chemotherapy
with an intravenous paclitaxel infusion.
Methods
Patients
Thirty Japanese outpatients (mean age 55 – 8.6
years [range 35–74]; 2 male and 28 female) who
received treatment with paclitaxel (80–330mg/day)
for breast, ovarian, or gastric cancer were eligible
subjects for this research. This clinical study was
approved by the Institutional Review Board for
Clinical Trials at Gunma University Hospital
(Maebashi, Japan). Written consent was obtained
from all patients after they were informed of the
study procedure.
Analysis of Ethanol Concentrations in
Exhaled Breath
The volume of ethanol administered and the
infusion rate of ethanol were calculated from the
volume of the paclitaxel infusion and the admin-
istration time. Immediately after administration
of the intravenous infusion to a subject, a bal-
loon-type gas detector tube (Kitagawa Gas De-
tector Tube System; Komyo Rikagaku Kogyo
KK, Kanagawa, Japan) was used to measure the
concentration of ethanol in exhaled breath. The
levels of aspartic acid aminotransferase (AST)
and alanine aminotransferase (ALT) were noted
from the medical records, and the alcohol drink-
ing history was taken from each patient.
Statistics
Correlations between the total amount of etha-
nol administered and the ethanol concentration
in exhaled breath, and between the intravenous
infusion speed and the ethanol concentration in
exhaled breath, were calculated using Pearson’s
correlation coefficient. Regression analysis was
applied to each combination.
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Results
Patient Characteristics, Treatment, and
Breath Ethanol Concentrations
The patient characteristics, the amount of
paclitaxel administered, the speed of the intra-
venous infusion, and the concentration of etha-
nol in exhaled breath are summarized in table I.
The average ethanol concentration in exhaled
breath immediately after the intravenous infu-
sion of paclitaxel was 0.028 – 0.015mg/L (range
0.00–0.06).
Hepatic function in all patients was assessed to
be within the normal range, as indicated by AST
and ALT values of 12–33U/L and 12–62U/L,
respectively.
Table I. Ethanol concentrations in exhaled breath of individual patients





















1 66 Female Breast 330 27.5 210 7.9 0.04
2 61 Female Ovarian 300 25.0 180 8.3 0.05
3 50 Female Breast 280 23.3 135 10.4 0.05
4 35 Female Ovarian 270 22.5 180 7.5 0.03
5 58 Female Ovarian 270 22.5 180 7.5 0.01
6 56 Female Breast 250 20.8 153 8.2 0.06
7 52 Female Ovarian 240 20.0 180 6.7 0.05
8 49 Female Ovarian 240 20.0 180 6.7 0.04
9 56 Female Ovarian 180 15.0 180 5.0 0.01
10 55 Female Breast 145 12.1 74 9.8 0.05
11 54 Female Breast 130 10.8 80 8.1 0.02
12 68 Female Gastric 120 10.0 108 5.6 0.03
13 45 Female Breast 120 10.0 70 8.6 0.04
14 60 Female Breast 120 10.0 99 6.1 0.03
15 60 Female Breast 120 10.0 95 6.3 0.03
16 53 Male Gastric 120 10.0 127 4.7 0.02
17 51 Female Breast 110 9.2 99 5.6 0.03
18 52 Female Breast 110 9.2 65 8.5 0.04
19 40 Female Breast 110 9.2 90 6.1 0.02
20 53 Female Breast 110 9.2 85 6.5 ND
21 52 Female Gastric 108 9.0 85 6.4 0.04
22 58 Female Breast 105 8.8 81 6.5 0.03
23 58 Female Breast 105 8.8 130 4.0 0.01
24 39 Female Breast 103 8.6 91 5.7 0.01
25 74 Female Breast 100 8.3 75 6.7 0.03
26 66 Female Breast 100 8.3 78 6.4 0.03
27 49 Female Breast 98 8.2 88 5.6 0.03
28 61 Female Ovarian 90 7.5 185 2.4 0.01
29 64 Female Breast 86 7.2 90 4.8 0.01
30 55 Male Gastric 80 6.7 100 4.0 ND
Average –SD 55– 8.6 155– 76 12.9 –6.3 119– 45 6.5 – 1.7 0.03 –0.02
ND= not detectable; SD = standard deviation.
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Relationship between Ethanol
Concentrations in Exhaled Breath
and the Total Volume or Infusion
Speed of Ethanol
The correlation coefficient between the total
amount of ethanol administered via the intra-
venous infusion and the ethanol concentration in
exhaled breath was weak (R2= 0.25; p = 0.055)
[figure 1a]. In contrast, the intravenous infusion
speed had a relatively stronger positive correla-
tion with the concentration of exhaled ethanol
(R2 = 0.49; p = 0.11) [figure 1b].
Discussion
More than 90% of ethanol is metabolized by
alcohol dehydrogenase (ADH) and aldehyde de-
hydrogenase 2 (ALDH2) in the liver.[7] It has
been reported that people with low ALDH2 ac-
tivity show hereditary sensitivity to the effects
of alcohol, and approximately 50% of Japanese
people are poor alcohol metabolizers.[8] Thus, the
percentage of Japanese people who experience
facial flush and heart palpitations in association
with elevated blood aldehyde concentrations after
drinking alcohol is larger than that of Europeans
and Americans. Inter-individual differences in al-
cohol metabolism are also larger in the Japanese
population. Therefore, there is a greater risk of
intoxication leading to a car accident in people
who have poor ethanol metabolism, because the
blood ethanol concentration remains high even
after consumption of a relatively small amount of
alcohol.
Ethanol is eliminated primarily by a saturable
(Michaelis-Menten) process.[8] Hence, the half-
life of ethanol changes according to the dose or
the rate of administration. Paclitaxel injections
contain 50% (v/v) ethanol; thus, if 300mg of
paclitaxel is injected, 25mL ethanol is also ad-
ministered. This amount is equivalent to 500mL
of beer or 60mL of whisky. Furthermore, be-
cause the first-pass effect does not apply to in-
travenous infusions, the effects of ethanol will be
greater than with oral administration. In this
study, an ethanol concentration in exhaled breath
that exceeded the threshold for drunk driving, as
specified in the Road Traffic Act, was not de-
tected in any patient, but there was one case that
reached more than 40% of the threshold. More-
over, a previous report described several cases
that exceeded the threshold defined by the law.[9]
The relationship between the ethanol concen-
tration in breath and that in blood has been in-
vestigated, and a method of deducing the blood
concentration from the concentration in breath
has been established. Moreover, when consider-
ing the CNS effects, the ethanol concentration in
breath (which reflects the arterial blood ethanol
concentration) is considered to be a more suitable
indicator than the venous blood ethanol concen-
a
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Fig. 1. Relationship between the ethanol concentration in exhaled
breath and (a) the total amount of ethanol administered via the in-
travenous paclitaxel infusion; and (b) the speed of the paclitaxel in-
fusion. The data-point markers represent observed data. The oblique
black data lines represent the fitted curves.
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tration. The ratio of venous blood ethanol con-
centrations to exhaled breath ethanol concen-
trations is approximately 2000 : 1.[7]
The average blood ethanol concentration esti-
mated from our findings was 0.06– 0.03mg/mL.
Webster et al. reported that the average plasma
ethanol concentration after administration of pacli-
taxel inCaucasian patientswas 0.07– 0.10mg/mL.[6]
When the average doses of paclitaxel in both
studies (155 – 76 and 293 – 35mg, respectively)
are taken into consideration, the estimated blood
ethanol concentrations may have been a little
higher in our study. The difference in the body
size between Japanese and Caucasian subjects
may have affected this.
Because ethanol has a fast elimination rate, its
concentrations steady state rapidly, and this is
why the plasma ethanol concentration at the end
of administration depends on the infusion speed.
Thus, the ethanol concentration in exhaled breath
after administration of paclitaxel is considered to
be affected by the infusion speed but not by the
total amount of ethanol administered. There
were several subjects who complained of facial
flush or light-headedness after the end of the in-
travenous infusion, which may have been a re-
sponse to the ethanol metabolite, acetaldehyde.[10]
In these cases, markers other than the breath
ethanol concentration should be considered, in
order to assess the degree of intoxication. In
general, patients with high sensitivity to ethanol
tend to present with symptoms of alcohol impair-
ment and also have impaired decision-making
ability.
The gender bias of the patients should be men-
tioned as a limitation of this study. Because most
patients in the study were outpatients with breast
cancer or ovarian cancer, the majority of the
patients were female. It has previously been shown
that when the same dose of ethanol is administered
to male and female subjects, higher blood concen-
trations are reached in females than in males,[11]
and this may have affected our results.
Conclusion
We have shown that the ethanol concentration
in exhaled breath after administration of pacli-
taxel is affected by the infusion speed rather than
by the total amount of ethanol administered.
However, it is difficult to predict from this in-
formation which patients will show a high breath
ethanol concentration. Hence, all outpatients
receiving paclitaxel should avoid driving from
hospital when possible and, if driving is un-
avoidable, they should drive only after taking a
sufficient break. The possible effects of the etha-
nol additive should be considered carefully when
administering drugs, such as paclitaxel, with a
high volume of ethanol additive.
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